These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24022619)

  • 1. Management of hyperphosphataemia in chronic kidney disease: summary of National Institute for Health and Clinical Excellence (NICE) guideline.
    Dasgupta I; Shroff R; Bennett-Jones D; McVeigh G;
    Nephron Clin Pract; 2013; 124(1-2):1-9. PubMed ID: 24022619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go.
    Rizk R
    BMC Nephrol; 2016 Jul; 17(1):75. PubMed ID: 27393192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
    Jamal SA; Vandermeer B; Raggi P; Mendelssohn DC; Chatterley T; Dorgan M; Lok CE; Fitchett D; Tsuyuki RT
    Lancet; 2013 Oct; 382(9900):1268-77. PubMed ID: 23870817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
    Mohammed I; Hutchison AJ
    J Ren Care; 2009 Mar; 35 Suppl 1():65-70. PubMed ID: 19222734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients.
    Nguyen HV; Bose S; Finkelstein E
    BMC Nephrol; 2016 Apr; 17(1):45. PubMed ID: 27121505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.
    Bernard L; Mendelssohn D; Dunn E; Hutchison C; Grima DT
    J Med Econ; 2013; 16(1):1-9. PubMed ID: 22857538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: A systematic review.
    Rizk R; Hiligsmann M; Karavetian M; Evers SM
    Nephrology (Carlton); 2016 Mar; 21(3):178-87. PubMed ID: 26246269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.
    Thompson M; Bartko-Winters S; Bernard L; Fenton A; Hutchison C; Di Iorio B
    J Med Econ; 2013; 16(6):744-55. PubMed ID: 23550810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].
    Skaguchi T; Shigematsu T
    Clin Calcium; 2009 Jun; 19(6):844-51. PubMed ID: 19483280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Real-world Cost-effectiveness Analysis of Sevelamer Versus Calcium Acetate in Korean Dialysis Patients.
    Cho JH; Jang HM; Jung HY; Choi JY; Park SH; Kim CD; Yang CW; Jin DC; Kim YL
    Clin Ther; 2018 Jan; 40(1):123-134. PubMed ID: 28291581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary management of phosphorus retention in chronic kidney disease: a review.
    Amiri FS
    Clin Exp Nephrol; 2015 Dec; 19(6):985-99. PubMed ID: 26032778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
    Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
    Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphate management in chronic kidney disease.
    Bhan I
    Curr Opin Nephrol Hypertens; 2014 Mar; 23(2):174-9. PubMed ID: 24445424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.
    Assimon MM; Mousa S; Shaker O; Pai AB
    Consult Pharm; 2010 Jan; 25(1):41-54. PubMed ID: 20211816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
    Negi S; Yamanaka S; Koreeda D; Yashiro M; Shigematsu T
    Clin Calcium; 2012 Oct; 22(10):1557-66. PubMed ID: 23023637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study.
    Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B
    Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal use of phosphate binders in chronic kidney disease.
    Sonikian M; Papachristou E; Goumenos DS
    Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should phosphate management be limited to the KDIGO/ KDOQI guidelines?
    Dhillon-Jhattu S; Sprague SM
    Semin Dial; 2018 Jul; 31(4):377-381. PubMed ID: 29671909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.